A citation-based method for searching scientific literature

Yongfeng Yu, Yongxin Ren, Jian Fang, Lejie Cao, Zongan Liang, Qisen Guo, Sen Han, Zimei Ji, Ye Wang, Yulan Sun, Yuan Chen, Xingya Li, Hua Xu, Jianying Zhou, Liyan Jiang, Ying Cheng, Zhigang Han, Jianhua Shi, Gongyan Chen, Rui Ma, Yun Fan, Sanyuan Sun, Longxian Jiao, Xiaoyun Jia, Linfang Wang, Puhan Lu, Qian Xu, Xian Luo, Weiguo Su, Shun Lu. Ther Adv Med Oncol 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




Proteasome Inhibitors Diminish c-Met Expression and Induce Cell Death in Non-Small Cell Lung Cancer Cells.
Yanhui Li, Su Dong, Arya Tamaskar, Heather Wang, Jing Zhao, Haichun Ma, Yutong Zhao. Oncol Res 2020
3
100

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
G R Oxnard, J C-H Yang, H Yu, S-W Kim, H Saka, L Horn, K Goto, Y Ohe, H Mann, K S Thress,[...]. Ann Oncol 2020
190
100

The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
John F Deeken, Wolfgang Löscher. Clin Cancer Res 2007
466
100


Scatter factor is a fibroblast-derived modulator of epithelial cell mobility.
M Stoker, E Gherardi, M Perryman, J Gray. Nature 1987
100

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: 
Safety, Efficacy, and Biomarkers.
Yakun Wang, Tianshu Liu, Gongyan Chen, Jifang Gong, Yuxian Bai, Tao Zhang, Nong Xu, Li Liu, Jianming Xu, Jianxing He,[...]. Oncologist 2022
3
100

Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.
Paul R Gavine, Yongxin Ren, Lu Han, Jing Lv, Shiming Fan, Wei Zhang, Wen Xu, Yuan Jie Liu, Tianwei Zhang, Haihua Fu,[...]. Mol Oncol 2015
82
100

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, D Ross Camidge. J Thorac Oncol 2017
212
100

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
164
100

Molecular testing of metastatic non-small cell lung cancer in the Asia-Pacific region.
Chong-Kin Liam, Emily Stone, Sita Andarini, Yong-Sheng Liam, David Chi-Leung Lam, Pyng Lee. Respirology 2020
3
100


Leptomeningeal metastases in non-small-cell lung cancer.
Haiying Cheng, Roman Perez-Soler. Lancet Oncol 2018
121
100



Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
Ryan J Hartmaier, Aleksandra A Markovets, Myung Ju Ahn, Lecia V Sequist, Ji-Youn Han, Byoung Chul Cho, Helena A Yu, Sang-We Kim, James Chih-Hsin Yang, Jong-Seok Lee,[...]. Cancer Discov 2023
1
100

MET amplification increases the metastatic spread of EGFR-mutated NSCLC.
Simon Baldacci, Zoulika Kherrouche, Vincent Cockenpot, Luc Stoven, Marie Christine Copin, Elisabeth Werkmeister, Nathalie Marchand, Maéva Kyheng, David Tulasne, Alexis B Cortot. Lung Cancer 2018
14
100

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Shun Lu, Jian Fang, Xingya Li, Lejie Cao, Jianying Zhou, Qisen Guo, Zongan Liang, Ying Cheng, Liyan Jiang, Nong Yang,[...]. Lancet Respir Med 2021
43
100

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
James Bean, Cameron Brennan, Jin-Yuan Shih, Gregory Riely, Agnes Viale, Lu Wang, Dhananjay Chitale, Noriko Motoi, Janos Szoke, Stephen Broderick,[...]. Proc Natl Acad Sci U S A 2007
100

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Alwin G Schuller, Evan R Barry, Rhys D O Jones, Ryan E Henry, Melanie M Frigault, Garry Beran, David Linsenmayer, Maureen Hattersley, Aaron Smith, Joanne Wilson,[...]. Clin Cancer Res 2015
52
100

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.
Qiming Wang, Sen Yang, Kai Wang, Shi-Yong Sun. J Hematol Oncol 2019
109
100

Physiological Signaling and Structure of the HGF Receptor MET.
Gianluca Baldanzi, Andrea Graziani. Biomedicines 2014
25
100

Targeting MET in cancer therapy.
Hong-Nan Mo, Peng Liu. Chronic Dis Transl Med 2017
105
100

A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, Daichi Fujimoto, Satoru Miura, Keiichi Ota, Yuichi Ozawa, Satoshi Hara, Junko Tanizaki, Koichi Azuma,[...]. Clin Cancer Res 2022
9
100

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.
D Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, Daniel Morgensztern, Rebecca Heist, Everett Vokes, Eric Angevin, David S Hong, Igor I Rybkin, Minal Barve,[...]. JTO Clin Res Rep 2021
3
100

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.
Simon Baldacci, Julien Mazieres, Pascale Tomasini, Nicolas Girard, Florian Guisier, Clarisse Audigier-Valette, Isabelle Monnet, Marie Wislez, Maurice Pérol, Pascal Dô,[...]. Oncotarget 2017
19
100

Palliative chemotherapy for pulmonary pleomorphic carcinoma.
Hyun-Mi Bae, Hye Sook Min, Se-Hoon Lee, Dong-Wan Kim, Doo Hyun Chung, Jong-Seok Lee, Young Whan Kim, Dae Seog Heo. Lung Cancer 2007
110
100

FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Luckson N Mathieu, Erin Larkins, Oladimeji Akinboro, Pourab Roy, Anup K Amatya, Mallorie H Fiero, Pallavi S Mishra-Kalyani, Whitney S Helms, Claire E Myers, Amy M Skinner,[...]. Clin Cancer Res 2022
21
100

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Jin-Ji Yang, Jian Fang, Yong-Qian Shu, Jian-Hua Chang, Gong-Yan Chen, Jian Xing He, Wei Li, Xiao-Qing Liu, Nong Yang, Caicun Zhou,[...]. Invest New Drugs 2021
16
100

MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer.
Lianghua Fang, Hui Chen, Zhenya Tang, Neda Kalhor, Ching-Hua Liu, Hui Yao, Shimin Hu, Pei Lin, Jin Zhao, Raja Luthra,[...]. Oncotarget 2018
9
100

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
302
100

Targeting MET Dysregulation in Cancer.
Gonzalo Recondo, Jianwei Che, Pasi A Jänne, Mark M Awad. Cancer Discov 2020
42
100

Savolitinib: First Approval.
Anthony Markham. Drugs 2021
18
100

The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma.
Jung Yong Hong, Moon Ki Choi, Ji Eun Uhm, Min Jae Park, Jeeyun Lee, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Joung Ho Han, Myung Ju Ahn. Med Oncol 2009
45
100

MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.
Henning Reis, Martin Metzenmacher, Moritz Goetz, Nikoleta Savvidou, Kaid Darwiche, Clemens Aigner, Thomas Herold, Wilfried E Eberhardt, Charlotte Skiba, Jörg Hense,[...]. Clin Lung Cancer 2018
44
100

Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Gillianne G Y Lai, Tse Hui Lim, John Lim, Perry J R Liew, Xue Lin Kwang, Rahul Nahar, Zaw Win Aung, Angela Takano, Yin Yeng Lee, Dawn P X Lau,[...]. J Clin Oncol 2019
66
100


Emerging therapeutic agents for advanced non-small cell lung cancer.
Ruqin Chen, Rami Manochakian, Lauren James, Abdel-Ghani Azzouqa, Huashan Shi, Yan Zhang, Yujie Zhao, Kexun Zhou, Yanyan Lou. J Hematol Oncol 2020
68
100

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
275
100

Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung.
Mony Ung, Isabelle Rouquette, Thomas Filleron, Kristell Taillandy, Laurent Brouchet, Jaafar Bennouna, Jean-Pierre Delord, Julie Milia, Julien Mazières. Clin Lung Cancer 2016
49
100

The role of MET in chemotherapy resistance.
Georgina E Wood, Helen Hockings, Danielle M Hilton, Stéphanie Kermorgant. Oncogene 2021
27
100

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski,[...]. Lancet Oncol 2020
191
100

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.
Pal Kaposi-Novak, Ju-Seog Lee, Luis Gòmez-Quiroz, Cédric Coulouarn, Valentina M Factor, Snorri S Thorgeirsson. J Clin Invest 2006
294
100

Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Alexis Cortot, Xiuning Le, Egbert Smit, Santiago Viteri, Terufumi Kato, Hiroshi Sakai, Keunchil Park, D Ross Camidge, Karin Berghoff, Soetkin Vlassak,[...]. Clin Lung Cancer 2022
6
100

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip,[...]. J Clin Oncol 2018
173
100

Untying the gordion knot of targeting MET in cancer.
Kanwal Raghav, Ann Marie Bailey, Jonathan M Loree, Scott Kopetz, Vijaykumar Holla, Timothy Anthony Yap, Fang Wang, Ken Chen, Ravi Salgia, David Hong. Cancer Treat Rev 2018
14
100

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
Toni K Choueiri, Daniel Y C Heng, Jae Lyun Lee, Mathilde Cancel, Remy B Verheijen, Anders Mellemgaard, Lone H Ottesen, Melanie M Frigault, Anne L'Hernault, Zsolt Szijgyarto,[...]. JAMA Oncol 2020
62
100

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
D Moro-Sibilot, N Cozic, M Pérol, J Mazières, J Otto, P J Souquet, R Bahleda, M Wislez, G Zalcman, S D Guibert,[...]. Ann Oncol 2019
77
100

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer.
Lingzhi Hong, Jianjun Zhang, John V Heymach, Xiuning Le. Ther Adv Med Oncol 2021
20
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.